BNP Paribas Financial Markets Boosts Stake in Savara Inc (NASDAQ:SVRA)

BNP Paribas Financial Markets raised its holdings in shares of Savara Inc (NASDAQ:SVRA) by 258.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 25,693 shares of the company’s stock after purchasing an additional 18,534 shares during the quarter. BNP Paribas Financial Markets’ holdings in Savara were worth $109,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. FMR LLC lifted its stake in shares of Savara by 9.6% during the 3rd quarter. FMR LLC now owns 1,083,893 shares of the company’s stock worth $4,596,000 after acquiring an additional 95,154 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after acquiring an additional 3,706 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after purchasing an additional 642,259 shares during the period. Intech Investment Management LLC bought a new stake in shares of Savara during the third quarter worth $174,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Savara by 54.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock worth $2,928,000 after purchasing an additional 242,249 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright lowered their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Performance

Shares of Savara stock opened at $3.02 on Thursday. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The company has a market capitalization of $518.29 million, a PE ratio of -7.02 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a 50-day simple moving average of $3.49 and a two-hundred day simple moving average of $4.00.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Research analysts expect that Savara Inc will post -0.45 EPS for the current fiscal year.

Insider Activity

In related news, Director Joseph S. Mccracken acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.13% of the company’s stock.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.